Deuruxolitinib 12 mg dosage should be stopped by individuals with alopecia areata, an autoimmune disorder that causes patchy hair loss, according to the FDA, according to Sun Pharma. However, patients receiving the 8 mg dose did not experience any thrombotic events or blood clot formations, and the FDA has not halted those trials, according to Sun Pharma.
According to Sun Pharmaceutical Industries Ltd. in India, the FDA has requested that testing on one dose of an investigational dermatological medicine be stopped due to the risk of blood clots, the firm said on Tuesday.
Deuruxolitinib 12 mg dosage should be stopped by individuals with alopecia areata, an autoimmune disorder that causes patchy hair loss, according to the FDA, according to Sun Pharma. However, patients receiving the 8 mg dose did not experience any thrombotic events or blood clot formations, and the FDA has not halted those trials, according to Sun Pharma.